SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (806)2/20/2008 11:21:19 AM
From: idos   of 810
 
>How much more unexpected bad news can there be?<

Not too many in the near term, maybe the results from ECOG?s Phase II Nexavar trial in refractory lung cancer patients (monotherapy trial) in mid 08 and much later in chemotherapy-naive melanoma patients (enrollment in the phase III trial is expected to end at Q208).

But on the positive side, Nexavar could do $500M in HCC in the long run.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News